Companies Atrium Therapeutics, Inc.
Atrium Therapeutics (RNA): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Atrium Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers88th pct.Of 17 peer CEOs
CEO pay, last three years
- $5,366,111FY2022
- $11,139,719FY2023
- $14,176,480FY2024
CEO total pay was $14,176,480 in fiscal 2024, up from $11,139,719 in fiscal 2023.
FY2024: salary $659,900 · bonus $0 · stock awards $10,748,480 · option awards $2,157,090
Executives and directors
Frequently asked questions
Who was the highest-paid executive at Atrium Therapeutics, Inc. in fiscal 2024?
As disclosed, Sarah Boyce (President and Chief Executive Officer) was the highest-paid executive at Atrium Therapeutics, Inc. in fiscal 2024, with total compensation of $14,176,480.
How does Atrium Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Sarah Boyce's total compensation ranked at the 88th percentile of Atrium Therapeutics, Inc.'s disclosed peer group.
What is Atrium Therapeutics, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Atrium Therapeutics, Inc.'s CEO-to-median employee pay ratio was 48:1.
How did shareholders vote on Atrium Therapeutics, Inc.'s executive compensation?
As disclosed, 76.11% of shareholders supported Atrium Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Atrium Therapeutics, Inc. spend in total on board compensation for fiscal 2024?
As disclosed, Atrium Therapeutics, Inc. reported total board compensation of $348,168 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sarah Boyce | $659,900 | $0 | $10,748,480 | $2,157,090 | $594,000 | $0 | $17,010 | $14,176,480 |
| President and Chief Executive Officer | ||||||||
| John Moriarty | 208,333 | 0 | 4,226,090 | 5,081,184 | 168,800 | 0 | 14,789 | 9,699,196 |
| Chief Legal Officer and Corporate Secretary | ||||||||
| Michael MacLean | 490,800 | 0 | 3,340,440 | 762,172 | 331,300 | 0 | 17,010 | 4,941,722 |
| Chief Financial Officer | ||||||||
| W. Michael Flanagan | 500,300 | 0 | 3,315,040 | 632,746 | 337,800 | 0 | 17,010 | 4,802,896 |
| Chief Scientific Officer | ||||||||
| Teresa McCarthy | 456,900 | 0 | 3,279,480 | 560,843 | 308,500 | 0 | 17,010 | 4,622,733 |
| Chief Human Resources Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Sarah Boyce | $14,176,480 | $11,139,719 | $5,366,111 | ↑ +3,036,761 |
| John Moriarty | 9,699,196 | — | — | — |
| Michael MacLean | 4,941,722 | 4,476,128 | 2,035,530 | ↑ +465,594 |
| W. Michael Flanagan | 4,802,896 | 4,885,961 | 2,065,986 | ↓ −83,065 |
| Teresa McCarthy | 4,622,733 | 3,726,393 | 2,265,809 | ↑ +896,340 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation philosophy is designed to align pay with company performance, attract and retain a competitive executive team, and establish a direct link between business results, individual executive performance, and total executive compensation. The program emphasizes a significant portion of at-risk compensation, including short-term cash incentives and long-term equity incentives, to align the interests of executive officers with those of stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Michael MacLean | OPTION | 2024-01-20 | — | — | 106,000 | — | $762,172 |
| John Moriarty | PSU | 2024-10-30 | — | — | 72,000 | — | 3,111,840 |
| W. Michael Flanagan | PSU | 2024-10-30 | — | — | 72,000 | — | 3,111,840 |
| Michael MacLean | PSU | 2024-10-30 | — | — | 72,000 | — | 3,111,840 |
| Sarah Boyce | PSU | 2024-10-30 | — | — | 234,000 | — | 10,113,480 |
| Teresa McCarthy | PSU | 2024-10-30 | — | — | 72,000 | — | 3,111,840 |
| W. Michael Flanagan | RSU | 2024-01-20 | — | — | 20,000 | — | 203,200 |
| Michael MacLean | RSU | 2024-01-20 | — | — | 22,500 | — | 228,600 |
| John Moriarty | RSU | 2024-08-01 | — | — | 25,000 | — | 1,114,250 |
| Teresa McCarthy | RSU | 2024-01-20 | — | — | 16,500 | — | 167,640 |
| Sarah Boyce | RSU | 2024-01-20 | — | — | 62,500 | — | 635,000 |
| W. Michael Flanagan | OPTION | 2024-01-20 | — | — | 88,000 | — | 632,746 |
| Sarah Boyce | OPTION | 2024-01-20 | — | — | 300,000 | — | 2,157,090 |
| Teresa McCarthy | OPTION | 2024-01-20 | — | — | 78,000 | — | 560,843 |
| John Moriarty | OPTION | 2024-08-01 | — | — | 160,000 | — | 5,081,184 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Michael MacLean | $228,600 | $3,111,840 | $762,172 | 75.9% |
| John Moriarty | 1,114,250 | 3,111,840 | 5,081,184 | 33.4% |
| W. Michael Flanagan | 203,200 | 3,111,840 | 632,746 | 78.8% |
| Sarah Boyce | 635,000 | 10,113,480 | 2,157,090 | 78.4% |
| Teresa McCarthy | 167,640 | 3,111,840 | 560,843 | 81.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Michael MacLean | Option | 1,917 | 22.34 | — |
| Teresa McCarthy | Option | 2,292 | 22.34 | — |
| W. Michael Flanagan | Option | 3,125 | 26.75 | — |
| Sarah Boyce | Option | 6,250 | 22.34 | — |
| Michael MacLean | RSU | 13,875 | — | 403,485 |
| Teresa McCarthy | RSU | 15,000 | — | 436,200 |
| Teresa McCarthy | RSU | 16,500 | — | 479,820 |
| W. Michael Flanagan | RSU | 20,000 | — | 581,600 |
| Michael MacLean | RSU | 22,500 | — | 654,300 |
| Michael MacLean | RSU | 25,000 | — | 727,000 |
| W. Michael Flanagan | RSU | 25,000 | — | 727,000 |
| Teresa McCarthy | RSU | 25,000 | — | 727,000 |
| John Moriarty | RSU | 25,000 | — | 727,000 |
| W. Michael Flanagan | RSU | 30,000 | — | 872,400 |
| Michael MacLean | Option | 35,547 | 14.22 | — |
| W. Michael Flanagan | Option | 36,969 | 14.22 | — |
| Teresa McCarthy | Option | 37,125 | 6.57 | — |
| Sarah Boyce | RSU | 37,500 | — | 1,090,500 |
| Teresa McCarthy | Option | 42,657 | 14.22 | — |
| W. Michael Flanagan | Option | 49,500 | 6.57 | — |
| Michael MacLean | Option | 50,875 | 6.57 | — |
| Teresa McCarthy | Option | 56,250 | 22.47 | — |
| Teresa McCarthy | Option | 60,125 | 10.16 | — |
| Sarah Boyce | RSU | 62,500 | — | 1,817,500 |
| W. Michael Flanagan | Option | 67,834 | 10.16 | — |
| Michael MacLean | RSU | 72,000 | — | 2,093,760 |
| W. Michael Flanagan | RSU | 72,000 | — | 2,093,760 |
| Teresa McCarthy | RSU | 72,000 | — | 2,093,760 |
| John Moriarty | RSU | 72,000 | — | 2,093,760 |
| W. Michael Flanagan | Option | 75,000 | 22.47 | — |
| Michael MacLean | Option | 77,084 | 22.47 | — |
| Michael MacLean | Option | 81,709 | 10.16 | — |
| Sarah Boyce | Option | 115,105 | 14.22 | — |
| Sarah Boyce | Option | 137,500 | 6.57 | — |
| John Moriarty | Option | 160,000 | 44.57 | — |
| Sarah Boyce | Option | 208,334 | 22.47 | — |
| Sarah Boyce | Option | 231,250 | 10.16 | — |
| Sarah Boyce | RSU | 234,000 | — | 6,804,720 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Simona SkerjanecIndependent | $15,260 | — | $865,554 | — | $0 | $880,814 |
| Troy Wilson, Ph.D., J.DIndependent · Human Capital | 71,908 | — | 374,989 | — | 0 | 446,897 |
| Noreen Henig, M.DIndependent · Audit · Nominating and Corporate Governance (Chair) | 55,500 | — | 374,989 | — | 0 | 430,489 |
| Carsten BoessIndependent · Audit (Chair) | 55,000 | — | 374,989 | — | 0 | 429,989 |
| Edward M. Kaye, M.DIndependent · Human Capital (Chair) · Nominating and Corporate Governance · Audit | 54,000 | — | 374,989 | — | 0 | 428,989 |
| Tamar ThompsonIndependent · Human Capital Management · Nominating and Corporate Governance | 49,000 | — | 374,989 | — | 0 | 423,989 |
| Jean KimIndependent · Audit | 47,500 | — | 374,989 | — | 0 | 422,489 |
| Sarah BoyceEmployee director | — | — | — | — | — | 0 |
| Arthur A. Levin, Ph.DEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $375,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $348,168 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $348,168 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Atrium Therapeutics as a peer
Companies that benchmark against RNA
6 companies name RNA as a compensation peer
The list of companies that name RNA as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ERAS ErascaPCVX VaxcyteRCKT Rocket PharmaceuticalsVERV Verve TherapeuticsPLRX Pliant TherapeuticsZNTL Zentalis PharmaceuticalsCRNX Crinetics PharmaceuticalsJANX Janux TherapeuticsKYMR Kymera TherapeuticsDYN Dyne TherapeuticsINBX Inhibrx IncSTOK Stoke TherapeuticsARCT Arcturus Therapeutics HoldingsBEAM Beam TherapeuticsVTYX Ventyx BiosciencesRAPT RAPT TherapeuticsIGMS IGM Biosciences
Peer reciprocity
The companies Atrium Therapeutics, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Stoke Therapeutics | 2025 | Ian Smith | $170,625 | $11,590,000 | $14,035,067 | $0 | $27,031,655 |
| 2 | Vaxcyte | 2025 | Grant Pickering | 800,000 | 4,300,159 | 8,714,048 | 630,000 | 14,458,937 |
| 3 | Atrium Therapeutics, Inc. | 2024 | Sarah Boyce | 659,900 | 10,748,480 | 2,157,090 | 594,000 | 14,176,480 |
| 4 | Janux Therapeutics | 2025 | David Campbell | 680,000 | 0 | 12,459,031 | 367,200 | 13,506,231 |
| 5 | Crinetics Pharmaceuticals | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 6 | Kymera Therapeutics | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 7 | Verve Therapeutics | 2024 | Sekar Kathiresan | 639,231 | 1,683,000 | 4,727,372 | 378,972 | 7,442,663 |
| 8 | Rapt Therapeutics | 2024 | Brian Wong | 630,000 | 0 | 5,927,297 | 416,000 | 6,979,539 |
| 9 | Beam Therapeutics | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 10 | Pliant Therapeutics | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 11 | Erasca | 2025 | Jonathan Lim | 670,400 | 0 | 3,135,250 | 482,688 | 4,298,838 |
| 12 | Rocket Pharmaceuticals | 2025 | Gaurav Shah | 671,076 | 806,751 | 1,613,377 | 403,048 | 3,510,241 |
| 13 | IGM Biosciences | 2023 | Fred Schwarzer | 646,797 | 868,050 | 1,336,743 | 355,738 | 3,207,328 |
| 14 | Inhibrx Inc | 2025 | Mark Lappe | 695,250 | 0 | 0 | 479,723 | 2,892,473 |
| 15 | Dyne Therapeutics | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
| 16 | Arcturus Therapeutics Holdings | 2025 | Joseph Payne | 750,000 | 0 | 941,000 | 0 | 1,691,000 |
| 17 | Zentalis Pharmaceuticals | 2025 | Julie Eastland | 700,000 | 99,772 | 56,975 | 441,000 | 1,300,731 |
| 18 | Ventyx Biosciences | 2024 | Raju Mohan | 621,920 | 0 | 303,800 | 342,045 | 1,283,015 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Atrium Therapeutics, Inc. | not disclosed | Option 80 · RSU 20 | not disclosed | Alpine |
| Arcturus Therapeutics Holdings | not disclosed | Options 100 | not disclosed | not disclosed |
| Beam Therapeutics | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Crinetics Pharmaceuticals | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Dyne Therapeutics | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Erasca | 120% | Options 100 | not disclosed | Alpine Rewards, LLC |
| IGM Biosciences | not disclosed | not disclosed | not disclosed | Aon |
| Inhibrx Inc | not disclosed | Option 100 | not disclosed | not disclosed |
| Janux Therapeutics | 90% | not disclosed | not disclosed | FW Cook |
| Kymera Therapeutics | 125% | not disclosed | No | Alpine Rewards |
| Pliant Therapeutics | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Pearl Meyer; Alpine Rewards |
| Rapt Therapeutics | 120% | Option 100 | not disclosed | Aon plc/Radford |
| Rocket Pharmaceuticals | not disclosed | not disclosed | not disclosed | Semler Brossy |
| Stoke Therapeutics | not disclosed | not disclosed | not disclosed | Aon |
| Vaxcyte | 105% | not disclosed | not disclosed | Pay Governance |
| Ventyx Biosciences | not disclosed | not disclosed | not disclosed | AON/Radford |
| Verve Therapeutics | not disclosed | not disclosed | not disclosed | Radford Data & Analytics from Aon plc |
| Zentalis Pharmaceuticals | 105% | not disclosed | not disclosed | Anderson Pay Advisors LLC / Pay Governance LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-10 | 80,649,100 | 25,309,060 | 5,307,944 | 76.11% | Passed |
| 2024 | 2024-06-13 | 67,573,742 | 995,207 | 5,179,358 | 98.55% | Passed |
| 2023 | 2023-06-15 | 52,276,295 | 613,109 | 84,702 | 98.84% | Passed |
| 2022 | 2022-06-15 | 42,097,420 | 492,828 | 46,999 | 98.84% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-10 | 76.11%a |
| 2024 | 2024-06-13 | 98.55%b |
| 2023 | 2023-06-15 | 98.84%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 48 : 1 |
|---|---|
| CEO total compensation | $14,176,480 |
| Median employee compensation | $297,345 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Simona Skerjanec | Director | 2026-02-27 | A | 20,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| W. Michael Flanagan | Director | 2026-02-27 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Troy Edward Wilson | Director | 2026-02-27 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Carsten Boess | Director | 2026-02-27 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Boyce | Director | 2026-02-27 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rocio Martin Hoyos | Chief Strategy Officer | 2026-04-20 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rocio Martin Hoyos | Chief Strategy Officer | 2026-04-20 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Brendan R. Winslow | Chief Financial Officer | 2026-04-20 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven George Hughes | Chief Medical Officer | 2026-04-20 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephanie Kenney | See Remarks | 2026-04-20 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Husam Younis | Chief Scientific Officer | 2026-04-20 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brendan R. Winslow | Chief Financial Officer | 2026-04-20 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Stephanie Kenney | See Remarks | 2026-04-20 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven George Hughes | Chief Medical Officer | 2026-04-20 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Kathleen P. Gallagher | Director | 2026-04-20 | A | 102,500 | 0 | 0 | Common | Form 4 ↗ |
| Kathleen P. Gallagher | Director | 2026-04-20 | A | 205,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Husam Younis | Chief Scientific Officer | 2026-04-20 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Brendan R. Winslow | Chief Financial Officer | 2026-09-18 | D | 6,742 | 9 | 60,341 | Common | Form 4 ↗ |
| Kathleen P. Gallagher | Director | 2026-09-18 | D | 11,632 | 9 | 104,106 | Common | Form 4 ↗ |
| W. Michael Flanagan | Director | 2026-09-18 | D | 22,812 | 9 | 204,167 | Common | Form 4 ↗ |
| Steven George Hughes | Chief Medical Officer | 2026-09-18 | D | 21,459 | 9 | 192,058 | Common | Form 4 ↗ |
| Stephanie Kenney | See Remarks | 2026-09-18 | D | 2,375 | 9 | 21,256 | Common | Form 4 ↗ |
| Sarah Boyce | Director | 2026-09-18 | D | 126,418 | 9 | 1,131,441 | Common | Form 4 ↗ |
| Husam Younis | Chief Scientific Officer | 2026-09-18 | D | 11,216 | 9 | 100,383 | Common | Form 4 ↗ |
| Rocio Martin Hoyos | Chief Strategy Officer | 2026-09-18 | D | 8,320 | 9 | 74,464 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (80 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Sarah Boyce. DEF 14A, filed 2025-04-29. Section “COMPENSATION TABLES” · page 36. As printed: 14,176,480. View filing ↗
- Section 01, John Moriarty. DEF 14A, filed 2025-04-29. Section “COMPENSATION TABLES” · page 36. As printed: 9,699,196. View filing ↗
- Section 01, Michael MacLean. DEF 14A, filed 2025-04-29. Section “COMPENSATION TABLES” · page 36. As printed: 4,941,722. View filing ↗
- Section 01, W. Michael Flanagan. DEF 14A, filed 2025-04-29. Section “COMPENSATION TABLES” · page 36. As printed: 4,802,896. View filing ↗
- Section 01, Teresa McCarthy. DEF 14A, filed 2025-04-29. Section “COMPENSATION TABLES” · page 36. As printed: 4,622,733. View filing ↗
- Section 03, Michael MacLean OPTION. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, John Moriarty PSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, W. Michael Flanagan PSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Michael MacLean PSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Sarah Boyce PSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Teresa McCarthy PSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, W. Michael Flanagan RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Michael MacLean RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, John Moriarty RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Teresa McCarthy RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Sarah Boyce RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, W. Michael Flanagan OPTION. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Sarah Boyce OPTION. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Teresa McCarthy OPTION. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, John Moriarty OPTION. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2025-04-29. Section “CEO Pay Ratio”. As printed: 48 : 1. View filing ↗
- Section 08, Simona Skerjanec. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 880,814. View filing ↗
- Section 08, Troy Wilson, Ph.D., J.D. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 446,897. View filing ↗
- Section 08, Noreen Henig, M.D. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 430,489. View filing ↗
- Section 08, Carsten Boess. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 429,989. View filing ↗
- Section 08, Edward M. Kaye, M.D. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 428,989. View filing ↗
- Section 08, Tamar Thompson. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 423,989. View filing ↗
- Section 08, Jean Kim. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 422,489. View filing ↗
- Section 08, Sarah Boyce. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Arthur A. Levin, Ph.D. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Simona Skerjanec 2026-02-27. Form 4, filed 2026-03-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, W. Michael Flanagan 2026-02-27. Form 4, filed 2026-03-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Troy Edward Wilson 2026-02-27. Form 4, filed 2026-03-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carsten Boess 2026-02-27. Form 4, filed 2026-03-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Boyce 2026-02-27. Form 4, filed 2026-03-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rocio Martin Hoyos 2026-04-20. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rocio Martin Hoyos 2026-04-20. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brendan R. Winslow 2026-04-20. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven George Hughes 2026-04-20. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephanie Kenney 2026-04-20. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Husam Younis 2026-04-20. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brendan R. Winslow 2026-04-20. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephanie Kenney 2026-04-20. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven George Hughes 2026-04-20. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathleen P. Gallagher 2026-04-20. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathleen P. Gallagher 2026-04-20. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Husam Younis 2026-04-20. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brendan R. Winslow 2026-09-18. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathleen P. Gallagher 2026-09-18. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, W. Michael Flanagan 2026-09-18. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven George Hughes 2026-09-18. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephanie Kenney 2026-09-18. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Boyce 2026-09-18. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Husam Younis 2026-09-18. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rocio Martin Hoyos 2026-09-18. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-10. Item 5.07 · say-on-pay result. As reported: 76.11% (votes for as printed: 80,649,100). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-14. Item 5.07 · say-on-pay result. As reported: 98.55% (votes for as printed: 67,573,742). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-16. Item 5.07 · say-on-pay result. As reported: 98.84% (votes for as printed: 52,276,295). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 348,168 + equity 0 + all other 0 = 348,168, summed across the director compensation table rows.
- Stoke Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Stoke Therapeutics's own proxy. As printed: 27,031,655. View filing ↗
- Vaxcyte, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vaxcyte's own proxy. As printed: 14,458,937. View filing ↗
- Atrium Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Atrium Therapeutics, Inc.'s own proxy. As printed: 14,176,480. View filing ↗
- Janux Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Janux Therapeutics's own proxy. As printed: 13,506,231. View filing ↗
- Crinetics Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Crinetics Pharmaceuticals's own proxy. As printed: 11,628,959. View filing ↗
- Kymera Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. View filing ↗
- Verve Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-25. CEO total compensation as printed in Verve Therapeutics's own proxy. As printed: 7,442,663. View filing ↗
- Rapt Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-14. CEO total compensation as printed in Rapt Therapeutics's own proxy. As printed: 6,979,539. View filing ↗
- Beam Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Beam Therapeutics's own proxy. As printed: 5,818,525. View filing ↗
- Pliant Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Pliant Therapeutics's own proxy. As printed: 5,462,901. View filing ↗
- Erasca, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Erasca's own proxy. As printed: 4,298,838. View filing ↗
- Rocket Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Rocket Pharmaceuticals's own proxy. As printed: 3,510,241. View filing ↗
- IGM Biosciences, Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in IGM Biosciences's own proxy. As printed: 3,207,328. View filing ↗
- Inhibrx Inc, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Inhibrx Inc's own proxy. As printed: 2,892,473. View filing ↗
- Dyne Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Dyne Therapeutics's own proxy. As printed: 2,076,868. View filing ↗
- Arcturus Therapeutics Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Arcturus Therapeutics Holdings's own proxy. As printed: 1,691,000. View filing ↗
- Zentalis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Zentalis Pharmaceuticals's own proxy. As printed: 1,300,731. View filing ↗
- Ventyx Biosciences, Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Ventyx Biosciences's own proxy. As printed: 1,283,015. View filing ↗
- Section 10a, Kymera Therapeutics reciprocity. DEF 14A. Kymera Therapeutics names Atrium Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗